![Dr. Robert Lee](https://www.dukehealth.org/sites/default/files/styles/doctor_profile/public/physician/w-robert-lee-md-med-ms.jpg?itok=DX4_MuHY)
De C-RT groep telde 547 patiënten en de H-RT groep 554. Het twaalf-jaars DFS-percentage was 56,1% (95%-bti 51,5-60,5) in de C-RT groep en 61,8% (57,2-66,0) in de H-RT groep, waarmee de noninferioriteit van H-RT ten opzichte van C-RT bevestigd werd (p<0,001). Twaalf-jaars cumulatieve incidentie van biochemisch falen (BF) was 17,0% met C-RT en 9,9% met H-RT (HR 0,55; 95%-bti 0,39-0,78). De incidentie van late graad 3 of hoger gastroïntestinale adverse events was 3,2% met C-RT versus 4,4% met H-RT (RR 1,39; 95%-bti 0,75-2,55) en de incidentie van late graad 3 of hoger genito-urinaire AEs was 3,4% versus 4,2% (1,26; 0,69-2,30).
De onderzoekers concluderen dat H-RT versus C-RT resulteerde in vergelijkbare DFS, superieure BF, en geen verschil in late graad 3 of hoger GI/GU AEs.
1.Lee RW, Dignam JJ, Amin MB et al. Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III noninferiority study comparing two factionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2024; epub ahead of print
Summary: Long-term analysis of RTOG 0415 found that among patients with low-risk prostate cancer and median 12.8 years follow-up, hypofractionated RT versus conventionally fractioated RT was noninferior for disease-free survival, superior for biochemical failure, while there were no significant differences in late grade ≥3 GI/GU toxicities.